SRD-001 not checked
Sardocor Corp. · AAV1/SERCA2a
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
- Main trialPhase 1/2
- “It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.”In the company’s words, NCT04703842 on ClinicalTrials.gov
- Other names
- AAV1/SERCA2a
Other drugs for Congestive Heart Failure
- Balcinrenone/dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv mecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2025 | Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction | |
| Phase 1Recruiting | Aug 2025 | Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026